DnB Asset Management AS bought a new position in shares of Amedisys Inc (NASDAQ:AMED) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 70,604 shares of the health services provider’s stock, valued at approximately $3,722,000. DnB Asset Management AS owned 0.21% of Amedisys at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Federated Investors Inc. PA increased its position in shares of Amedisys by 2.3% during the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock valued at $122,000 after acquiring an additional 44 shares in the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Amedisys by 0.5% during the second quarter. State Board of Administration of Florida Retirement System now owns 19,658 shares of the health services provider’s stock valued at $1,235,000 after acquiring an additional 93 shares in the last quarter. Suntrust Banks Inc. increased its position in shares of Amedisys by 4.3% during the second quarter. Suntrust Banks Inc. now owns 5,702 shares of the health services provider’s stock valued at $358,000 after acquiring an additional 237 shares in the last quarter. ETRADE Capital Management LLC increased its position in shares of Amedisys by 4.7% during the second quarter. ETRADE Capital Management LLC now owns 6,409 shares of the health services provider’s stock valued at $403,000 after acquiring an additional 285 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Amedisys by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,348 shares of the health services provider’s stock valued at $1,404,000 after acquiring an additional 410 shares during the period. Institutional investors own 94.93% of the company’s stock.
A number of brokerages have recently issued reports on AMED. Zacks Investment Research downgraded shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Friday. Mizuho restated a “buy” rating and set a $65.00 target price (up previously from $55.00) on shares of Amedisys in a research note on Wednesday, November 8th. Royal Bank of Canada reiterated a “hold” rating on shares of Amedisys in a research note on Monday, October 23rd. BidaskClub cut shares of Amedisys from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. Finally, William Blair restated an “outperform” rating on shares of Amedisys in a report on Tuesday, November 21st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the stock. Amedisys has a consensus rating of “Hold” and an average price target of $61.09.
Amedisys Inc (NASDAQ AMED) traded down $0.94 during trading hours on Friday, reaching $51.42. 262,284 shares of the company were exchanged, compared to its average volume of 312,119. The stock has a market capitalization of $1,745.04, a PE ratio of 24.60, a price-to-earnings-growth ratio of 1.07 and a beta of 0.73. Amedisys Inc has a 12 month low of $45.18 and a 12 month high of $65.91. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.33 and a quick ratio of 1.33.
Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, November 7th. The health services provider reported $0.56 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.02. The business had revenue of $380.20 million during the quarter, compared to analysts’ expectations of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter last year, the company posted $0.36 earnings per share. equities analysts anticipate that Amedisys Inc will post 2.24 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “DnB Asset Management AS Acquires Shares of 70,604 Amedisys Inc (AMED)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/04/70604-shares-in-amedisys-inc-amed-acquired-by-dnb-asset-management-as.html.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.